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Background: Reports of serious joint adverse events (AEs) due to osteonecrosis were noted during
randomized placebo-controlled clinical trials of monoclonal antibodies to nerve growth factor (NGF),
including tanezumab and fulranumab.
Methods: All available medical records from subjects with reported cases of osteonecrosis, as well as
records of subjects who underwent joint replacement during these studies, were reviewed by an in-
dependent adjudication committee that was established by each company; the committees were
different for each company and included distinct individual experts. Cases were categorized as having
deﬁnite osteonecrosis, normal or rapid progression of osteoarthritis (OA), another diagnosis or unable to
determine the underlying diagnosis.
Results: The vast majority of investigator reported cases of osteonecrosis were adjudicated as either
normal or rapid progression of OA. Indeed, the syndrome of rapid progression of OA associated with
chondrolysis and bone destruction appears to be a safety signal that is associated with not only
increasing doses of anti-NGF antibodies but also concomitant therapy with nonsteroidal anti-inﬂam-
matory drugs.
Conclusions: These results have implications for future clinical trials of anti-NGF agents in OA and other
painful conditions.
Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Monoclonal antibodies to Nerve Growth Factor (NGF), including
tanezumab and fulranumab, were developed as treatments for
acute and chronic pain, including that associated with osteoar-
thritis (OA), chronic low back pain and other diseases1e16. Unex-
pected adverse events (AEs) described by study investigators as
osteonecrosis were reported in 87 patients during Phase II and III
trials in the tanezumab development program leading the Division
of Analgesia, Anesthetic and Addiction Products of the U.S. Food
and Drug Administration (FDA), in 2010, to place a temporary
partial clinical hold on studies of tanezumab for all indications
other than cancer pain. This partial clinical hold subsequently wasM.C. Hochberg, c/o Division
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eoarthritis Research Society Internextended to all anti-NGF monoclonal antibodies in clinical devel-
opment, including fulranumab.
Pﬁzer, the sponsor of the tanezumab development program,
formed an Adjudication Committee, composed of a bone patholo-
gist, orthopedic surgeons and rheumatologists, that reviewed,
adjudicated, and classiﬁed the reported cases of osteonecrosis.
While no radiologists were included in this Adjudication Commit-
tee, several of the rheumatologists had experience in reading hip
and knee radiographs in both clinical trials and observational
epidemiologic studies. The methods and results of the adjudication
process and its implications for the further clinical development of
tanezumab were presented at a meeting of the U.S. FDA held in
March 201217 and at the 2012 annual meeting of the American
College of Rheumatology18 and will be summarized brieﬂy in this
manuscript. In addition, this manuscript also will summarize
brieﬂy the methods and results of a similar process conducted by
Janssen Research and Development, LLC for cases reported during
the clinical development program for fulranumab that were pre-
sented at the same 2012 meeting of the U.S. FDA19 and at the 2013
annual meeting of the Osteoarthritis Research Societyational.
Fig. 1. Rate per 1000 person-years of reported osteonecrosis by dose of tanezumab in
the tanezumab-NSAID combination group in the phase III OA trials.
Table II
Results of Adjudication of 87 cases of reported osteonecrosis
Osteonecrosis (ON) 2 (2.3%)
Worsening OA 51 (58.6%)
Normal progression 17 (33.3%)
Rapid progression 34 (66.7%)
Other diseases 21 (24.1%)
Not enough information to distinguish OA from ON 8 (9.2%)
Lack of consensus 5 (5.8%)
M.C. Hochberg / Osteoarthritis and Cartilage 23 (2015) S18eS21 S19International20. It should be noted that different adjudication
committees were used by the different companies. The complete
description of the demographic and clinical characteristics of the
underlying study populations can be found in the respective
brieﬁng documents17,19.
Tanezumab adjudication
Reports of osteonecrosis were analyzed over the entire phase III
OA studies and over the phase II chronic low back pain studies;
there were no reports of osteonecrosis in any of the other phase I or
II studies in other painful conditions. A total of 87 subjects with one
ormore AEs of osteonecrosis were reported; 81 cases were enrolled
in phase III studies in OA and the remaining six cases were enrolled
in phase II studies in chronic low back pain. A total of 95 sites were
affected; the majority of occurrences were in the hip (52 [54.7%])
followed by the knee (29 [30.5%]) and shoulder (12 [12.6%]) in
declining order of frequency. The number of reported cases of
osteonecrosis and the rate of occurrence by treatment group
assignment for the combined phase III OA and phase II chronic low
back pain databases are shown in Table I. Both the number of cases
and rate per 1000 person-years of exposure were numerically
higher in the group that was randomized to a combination of
tanezumab with a nonsteroidal anti-inﬂammatory drug (NSAID);
the NSAIDs used in these studies included naproxen 500 mg twice
daily, celecoxib 100 mg twice daily or diclofenac 75 mg twice daily.
Within the tanezumab-NSAID combination group, there was a
signiﬁcant doseeresponse relationship for the rate per 1000
person-years with increasing doses of tanezumab from 2.5 to
5e10 mg given intravenously every 8 weeks (Fig. 1)17.
The Adjudication Committee reviewed all of the case reports
including all available ofﬁce notes and radiology and operative re-
ports and examined all available images including radiographs,
computed tomographs and magnetic resonance images. In addi-
tion, the bone pathologist reviewed all available pathology reports
as well as histopathologic slides from 23 (26.4%) cases. Cases were
classiﬁed as having osteonecrosis, worsening OA, another condi-
tion, or not enough information to distinguish the condition;
radiologic features used in deﬁning these entities are described in
Pﬁzer FDA Brieﬁng Document17, pages (44e45). Those with wors-
ening OA were further subclassiﬁed into normal or rapid progres-
sion or not enough information to distinguish. Those with rapid
progression of OA were further subclassiﬁed into type 1 or type 2
based on the amount of decline in joint space width in 1 year,
greater than or less than 2 mm, or the presence of chondrolysis and
bone destruction not normally seen in end-stage OA21e28.
Results of the adjudication process are shown in Table II. Only 2
(2.3%) of the 87 subjects reported as having osteonecrosis were
adjudicated by the committee as having primary osteonecrosis; one
case occurred in the right shoulder of a patient randomized to
tanezumab 10 mg as monotherapy for treatment of painful right
knee OA, and the other case occurred in the right hip of a patientTable I
Investigator reported cases of osteonecrosis in phase 3 OA and phase 2 chronic low
back pain studies combined
Treatment No. subjects Person-years No. cases Rate*
Placebo 1300 382 0 0
TZB monotherapy 5371 3103 28 9
TZB and NSAID 3392 2301 55 23.9
Active comparators 1649 765 4 5.2
TZB ¼ tanezumab, NSAID ¼ nonsteroidal anti-inﬂammatory drug.
Active comparators included naproxen, diclofenac, celecoxib and oxycodone
depending on the study protocol.
* Rate per 1000 patient-years.randomized to tanezumab 5 mg as monotherapy for treatment of
painful left knee OA. Both cases were noted on routine end of study
radiographs and neither joint was symptomatic.
Worsening OAwas the adjudicated diagnosis in 51cases with an
AE report of osteonecrosis. Of interest, two-thirds of these cases of
worsening OA were adjudicated as having rapidly progressive OA;
all but three of them had type 2 rapidly progressive OA with bone
destruction out of proportion to that usually seen in normally
progressive OA. In the other category, the most common individual
adjudicated conditionwas subchondral insufﬁciency fracture of the
knee, erroneously referred to as spontaneous osteonecrosis of the
knee29,30.
The adjudication committee identiﬁed another condition in 21
(24.1%) cases; themost common other conditionwas a subchondral
insufﬁciency fracture of the knee. In 8 (9.2%) events there was not
enough information to deﬁnitively assess the event; for most of
these events, there were no or poor quality images available for
review. Finally, the adjudication committee was unable to reach
consensus in 5 (5.8%) of cases; none of these were felt by any
member of the adjudication committee to have osteonecrosis.Fulranumab adjucation
The process used by Janssen Research and Development was
similar to that employed by Pﬁzer in that it used an expert, inde-
pendent panel to assess cases with the intent of determining di-
agnoses of cases based on clinical and imaging data. The
adjudication committee was composed of experts in orthopedic
surgery, radiology and rheumatology.
All joint replacement cases and signiﬁcant joint-related AEs not
resulting in joint replacement in the fulranumab development
program reported as of July 2011 were adjudicated. A total of 88 of
1353 subjects treated in the nine Phase I and II studies of fulranu-
mab had at least one joint replacement; most (76 [86.4%]) treated
with fulranumab (Table III). Therewas evidence of a doseeresponse
Table III
Investigator reported cases of total joint replacement in phase II studies in the
fulranumab development program
Treatment No. subjects Person-years No. cases Rate*
Placebo 303 216.3 11 50.8
Fulranumab 783 872.6 75 86.0
Oxycodone 50 25.1 1 39.8
* Rate per 1000 patient-years.
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occurring in subjects randomized to fulranumab at a dose of 10 mg
IV every 8 weeks [see Table 13 in Brieﬁng document19].
One hundred eight joints, including 101 joint replacement and
seven other joint-related AEs were adjudicated; 17 of the total joint
replacement were initially ascribed to osteonecrosis. The radiologic
features used in deﬁning these entities are described in Janssen FDA
Brieﬁng Document19, pages (56e57). Overall, the majority of the
joint replacements were classiﬁed as normal progression of OA (65
[64%]); 18 (18%) were classiﬁed as rapidly progressive OA, 14 (14%)
had insufﬁcient information to assess and four were considered as
not applicable as they were revisions of joint replacement cases. No
cases were assessed as having osteonecrosis.
Among the 18 cases of rapidly progressive OA, 7 (four knees and
three hips) were type 1 and 11 (four knees and seven hips) were
type 2. All 18 cases that had an original radiologic diagnosis of
osteonecrosis in the AE reports were as either rapidly progressive
or normal progression of OA.
The adjudication committee concluded that rapidly progressive
OA may occur in association with fulranumab use and is a safety
signal, as all of the 18 cases adjudicated as rapidly progressive OA
occurred in fulranumab-treated patients.
Discussion
Rapidly progressive OA, with either a decline in joint space
width of 2 mm or greater in 1 year or chondrolysis and bone
destruction and fragmentation in excess of that normally seen in
OA, appears to be safety signal with treatment with monoclonal
antibodies to NGF. The number of cases and rate of occurrence was
signiﬁcantly greater in patients treated with tanezumab in combi-
nation with NSAIDs; the vast majority (85 percent) of patients
enrolled in the fulranumab development programwere also taking
NSAIDs, so this potential interaction was not examined. Finally,
there appeared to be a doseeresponse relationship with the
occurrence of rapidly progressive OA occurring with the highest
doses of these agents administered.
The mechanism(s) underlying this AE are not understood at
present31. It has been suggested that the occurrence of rapidly
progressive OA might represent a form of neuropathic arthropathy,
a progressive disease of joints caused by nerve damage resulting in
the loss of ability to feel pain in the joint in combination with
reduced joint proprioception32. This might reﬂect as well the
interaction with use of NSAIDs leading to a form of analgesic
arthropathy, previously described with the use of indomethacin33.
Another possible explanation for the apparent role of NSAIDs is the
effect of this class of drugs on inhibiting bone healing, since sub-
chondral microfractures are a pathologic feature hypothesized to
occur in rapidly progressive OA34e38.
Hence, if there is to be future clinical development of these
agents for treatment of pain due to OA and other musculoskeletal
conditions, it will be necessary to limit their use to patients not
taking NSAIDs and to use the lowest effective doses in order to
mitigate risk. In addition, it will be necessary to prospectively
adjudicate all serious joint-related AEs with committees thatinclude not only bone pathologists, orthopedic surgeons and
rheumatologists, but also radiologists with expertise in musculo-
skeletal disease.
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